| Literature DB >> 30089781 |
Laura Ponson1,2, Marie Gomot3, Romuald Blanc4,5, Catherine Barthelemy3, Sylvie Roux3, Arnold Munnich6,7, Serge Romana6,8, Nadia Aguillon-Hernandez3, Valérie Malan6,8, Frédérique Bonnet-Brilhault3,4.
Abstract
Phelan-McDermid syndrome is related to terminal 22q13 deletions of various sizes affecting the SHANK3 gene. In this neurodevelopmental disorder, behavioural symptoms of autism spectrum disorder (ASD) are reported in half of cases. Extensive clinical and neurophysiological characterization is lacking to understand the genotype-phenotype correlation. Eighteen patients (8 males, mean age 12.7 years, SD = 9.2) with known 22q13 deletions were fully explored with determination of deletion size, along with behavioural, language and cognitive standardized assessments. Neurophysiological indices previously reported to be altered in autism (i.e., eye tracking in a social/non-social task and auditory evoked potential mismatch) were also recorded. Thirty-nine percent met ASD clinical criteria, exceeding cut-off scores on both ADI-R (Autism Diagnosis Interview based on the period spanning 4-5 years of age) and ADOS-2 (Autism Diagnosis Observation Schedule for the current period). All patients had intellectual disability and language disability. Deletion size was significantly correlated with expressive and receptive language disability but not with ASD standardized assessment scores. Developmental Quotient tended to be lower in patients with the largest deletions. Using Eye Tracking, smaller pupil size, which is typically described in ASD, was not observed in these patients. Furthermore, atypical shortened latency of mismatch negativity response previously reported in ASD was not observed, whereas the N250 pattern, related to language, was affected. Language disability combined with cognitive deficits may lead to autistic behavioural symptoms, but with different neurophysiological networks compared to typical autism. These results highlight the indication for early speech therapy rather than intensive autism programme to treat these patients.Entities:
Mesh:
Year: 2018 PMID: 30089781 PMCID: PMC6082846 DOI: 10.1038/s41398-018-0212-9
Source DB: PubMed Journal: Transl Psychiatry ISSN: 2158-3188 Impact factor: 6.222
Summary of the 22q13 deletions characterized by array CGH
| Patient number | Genomic coordinates | Chromosomal region | Size of the deletion (Mb) |
|---|---|---|---|
| 1 | arr[GRCh37] 22q13.2.q13.33 (42982735 × 243006204_51193680 × 1) | 22q13.2.q13.33 | 8.187 |
| 1 | arr[GRCh37] 22q13.2 q13.33 (43454452 × 2,43484726_51193680 × 1) | 22q13.2q13.33 | 7.708 |
| 1 | arr[GRCh37] 22q13.31q13.33 (44889875 × 2,45002243_51193680 × 1) | 22q13.31q13.33 | 6.191 |
| 1 | arr[GRCh37] 22q13.33 (46547478 × 246591347–51193680 × 1) | 22q13.33 | 4.602 |
| 1 | arr[GRCh37] 22q13.31q13.33 (46988921 × 247046025_51,193,680 × 1) | 22q13.31q13.33 | 4.147 |
| 1 | arr[GRCh37] 22q13.31q13.33 (47244365 × 2,47308036_51193680 × 1) | 22q13.31q13.33 | 3.885 |
| 1 | arr[GRCh37] 22q13.32 q13.33 (48538897 × 2,48600735_51193680 × 1) | 22q13.32q13.33 | 2.592 |
| 1 | arr[GRCh37] 22q13.32q13.33 (49286818 × 2,49371757 × 1) | 22q13.32q13.33 | 1.80 |
| 1 | arr[GRCh37] 22q13.33(49647323 × 24975283451,149,235 × 1,51,151,912 × 2) | 22q13.33 | 1.396 |
| 1 | arr[GRCh37] 22q13.33 (50131,773 × 2,50,172,917_51,193,680 × 1) | 22q13.33 | 1.020 |
| 1 | arr[GRCh37] 22q13.33 (51123491_51304566 × 1) | 22q13.33 | 0.181 |
| 4 | arr[GRCh37] 22q13.33 (51121513 × 2,51122452–51193680 × 1) | 22q13.33 | 0.071 |
| 1 | arr[GRCh37] 22q13.33 (51,121,513 × 2,51,122,452 × 1) | 22q13.33 | 0.056 |
| 1 | arr[GRCh37] 22q13.33(51115076 × 2,51116,12851,145299 × 1,51,146,403 × 2) | 22q13.33 | 0.029 |
Genomic coordinates are indicated according to the ISCN (International System for Human Cytogenomic Nomenclature) 2016. CGH comparative genomic hybridization
Fig. 1Individual results for pupil dilation measurements.
Pupil dilation in standard deviation by age (SDA) is presented for each patient in face and object conditions. Patient results are colour coded as follows: Red for criteria exceeding cut-off scores for both ADI-R and ADOS-2; yellow when meeting only ADI-R criteria and blue when criteria do not exceed both cut-off scores
Fig. 2Individual results for auditory evoked potential measurements.
Amplitude and latency in standard deviation by age (SDA) are presented for each patient, for MMN in nFz, nCz, pM1 and pM2 positions. As in Fig. 1, results colour coded according ASD assessment profiles
Fig. 3Individual results for auditory evoked potential measurements.
Amplitude and latency in SD by age (SDA) are presented for each patient, for N250 in nFz, nCz, pM1 and pM2 positions. As in Fig. 1, results colour coded according ASD assessment profiles